Advanced search
Publication Cover
Bioscience, Biotechnology, and Biochemistry Volume 70, 2006 - Issue 9
Journal homepage
173
Views
26
CrossRef citations to date
0
Altmetric
Original Articles

Kinetics of Renin Inhibition by Sodium Houttuyfonate Analogs

Lujiang YUANDepartment of Human Nutritional Sciences, University of Manitoba;Chemistry Institute of Pharmaceutical Resources, Southwest University
,
Jianping WUDepartment of Human Nutritional Sciences, University of Manitoba
,
Rotimi E. ALUKODepartment of Human Nutritional Sciences, University of Manitoba
&
Xiaoli YESchool of Life Science, Southwest University
Pages 2275-2280 | Received 12 Apr 2006, Accepted 26 May 2006, Published online: 22 May 2014

  • 1) Brunner, H. R., Laragh, J. H., Baer, L., Newton, M. A., Goodwin, F. T., Krakoff, L. R., Bard, R. H., and Buhler, F. R., Essential hypertension: renin and aldosterone, heart attack and stroke. New Engl. J. Med., 286, 441–449 (1972).
  • 2) Waeber, B., Nussberger, J., and Brunner, H. R., The renin-angiotensin system: role in experimental and human hypertension. In “Hypertension,” eds. Birkenhager, W. H., and Reid, J. L., Elsevier Science Publishing, Amsterdam, pp. 489–519 (1986).
  • 3) Fouad-Tarazi, F., Bumpus, M., Khosla, M., and Healy, B., The renin-angiotensin system and treatment of heart failure. Am. J. Med., 84 (Suppl. 3A), 83–86 (1988).
  • 4) Peach, M. J., Renin-angiotensin system: biochemistry and mechanisms of action. Physiol. Rev., 57, 313–370 (1997).
  • 5) Maibaum, J., and Feldman, D. L., Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin. Ther. Patents, 13, 589–603 (2003).
  • 6) Zaman, M. A., Oparil, S., and Calhyoun, D. A., Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov., 1, 621–636 (2002).
  • 7) Brunner, H. R., Gavras, H., and Wacber, B., Oral angiotensin-comverting enzyme inhibitor in long-term treatment of hypertensive patients. Ann. Intern. Med., 90, 19–23 (1979).
  • 8) Seseko, S., and Kaneko, Y., Cough associated with the use of captopril. Arch. Intern. Med., 145, 1524–1529 (1985).
  • 9) Fisher, N. D., and Hollenberg, N. K., Is there a future for renin inhibitors? Expert Opin. Invest. Drugs, 10, 417–426 (2001).
  • 10) Stanton, A., Potential of renin inhibition in cardiovascular disease. J. Renin Angiotensin Aldosterone Syst., 4, 6–10 (2003).
  • 11) Ondetti, M. A., and Cushman, D. W., Enzymes of the renin-angiotensin system and their inhibitors. Ann. Rev. Biochem., 51, 283–308 (1982).
  • 12) Cumin, F., Evin, G., Fehrentz, J. A., Seyer, R., Castro, B., Menard, J., and Corvol, P., Inhibition of human renin by synthetic peptides derived from its prosegment. J. Biol. Chem., 260, 9154–9157 (1985).
  • 13) Jiangsu New Medical College, Zhongyao Dacidian (Encyclopaedia of ChineseTraditional Medicine), the People’s Publishing Company, Shanghai, 1986.
  • 14) The Pharmacopoeia Committee of China, The Chinese Pharmacopoeia, Vol. I, The Chemical Industry Publishing House, Beijing, 2000.
  • 15) Wang, D., Yu, Q., Eikstadt, P., Hammond, D., and Feng, Y., Studies on adjuvanticity of sodium houttuyfonate and its mechanism. Int. Immunopharmacol., 2, 1411–1418 (2002).
  • 16) Ye, X. L., Li, X. G., and Yuan, L. J., Relationship between the antibacterial and immunologic activities of houttuyfonate homologues and their surface activities. J. Asian Nat. Prod. Res., 8, 327–334 (2006).
  • 17) Ye, X. L., Li, X. G., and Yuan, L. J., Effect of the surface activity on the antibacterial activity of octadecanoyl acetal sodium sulfite series. Colloids Surf. A, 268, 85–89 (2005).
  • 18) Yuan, L. J., Li, X. G., and He, H. M., Effects of sodium houttuyfonate analogues on lysozme activity both in vitro and in vivo. Chinese J. Trad. Med., 20, 268–271 (2005).
  • 19) Li, X. G., Yuan, L. J., and He, H. M., Chinese Patent 100044932 (Feb. 27, 2004).
  • 20) Wang, G. T., Chung, C. C., Holzman, T. F., and Krafft, G. A., A continuous fluorescence assay of renin activity. Anal. Biochem., 210, 351–359 (1993).
  • 21) Holzman, T. F., Chung, C. C., Edalji, R., Egan, D. A., Martin, M., Gubbins, E. J., Krafft, G. A., Wang, G. T., Thomas, A. M., Rosenberg, S. H., and Hutchins, C., Characterization of recombinant human renin: kinetics, pH-stability, and peptidomimetic inhibitor binding. J. Prot. Chem., 10, 553–563 (1991).
  • 22) Sibanda, B. L., Blundell, T., Hobart, P. M., Fogliano, M., Bindra, J. S., Dominy, B. W., and Chirgwin, J. M., Computer graphics modeling of human renin: specificity, catalytic activity and intron-exon junctions. FEBS Lett., 174, 102–111 (1984).
  • 23) Rahuel, J., Rasetti, V., Maibaum, J., Rueger, H., Goschke, R., Cohen, N. C., Stutz, S., Cumin, F., Fuhrer, W., Wood, J. M., and Grutter, M. G., Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol., 7, 493–504 (2000).
  • 24) Wood, J. M., Maibaum, J., Rahuel, J., Grutter, M. G., Cohen, N. C., Rasetti, V., Ruger, H., Goschke, R., Stutz, S., Fuhrer, W., Schilling, W., Rigollier, P., Yamaguchi, Y., Cumin, F., Baum, H. P., Schnell, C. R., Herold, P., Mah, R., Jensen, C., O’Brien, E., Stanton, A., and Bedigian, M. P., Structure-based design of aliskrien, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun., 308, 698–705 (2003).
  • 25) Sueiras-Diaz, J., Jones, M., Szelke, M., Deinum, J., Svensson, L., Westerlund, C., and Sohtell, M., Synthesis and biological activity of potent low molecular weight renin inhibitors. J. Peptide Res., 50, 248–261 (1997).
  • 26) Corvol, P., Chauveau, D., Jeunemaitre, X., and Menard, J., Human renin inhibitor peptides. Hypertension, 16, 1–11 (1990).
  • 27) Evin, G., Devin, J., Castro, B., Menard, J., and Corvol, P., Synthesis of peptides related to the prosegment of mouse submaxillary gland renin precursor: an approach to renin inhibitors. Proc. Natl. Acad. Sci. USA, 81, 48–52 (1984).
  • 28) Pfeiffer, F. R., Hoke, S. C., Miao, C. K., Tedeschi, R. E., Pasteernak, J., Hahn, R., Erickson, R. W., Levin, H. W., Burton, C. A., and Weisbach, J. A., Lysophosphatidylethanolamine and 2-desoxylsophosphatidylethanolamine derivatives. 1. Potential renin inhibitors. J. Med. Chem., 14, 493–495 (1971).
  • 29) Toda, N., Miyazaki, M., Etoh, Y., Kubota, T., and Iizuka, K., Human renin inhibiting dipeptide. Eur. J. Pharmacol., 129, 393–396 (1986).
  • 30) Poulsen, K., Burton, J., and Haber, E., Competitive inhibitors of renin. Biochemistry, 12, 3877–3882 (1973).
  • 31) Kokubu, T., Ueda, E., Fujimoto, S., Hiwada, K., Kato, A., Akutsu, H., and Yamamura, Y., Peptide inhibitors of the renin-angiotensin system. Nature, 217, 456–457 (1968).
  • 32) Kokubu, T., Hiwada, K., Sato, Y., Iwata, T., Imamura, Y., Matsueda, R., Yabe, Y., Kogen, H., Yamazaki, M., Iijima, Y., and Baba, Y., Highly potent and specific inhibitors of human renin. Biochem. Biophys. Res. Commun., 118, 929–933 (1984).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.